News Focus
News Focus
Followers 71
Posts 4827
Boards Moderated 0
Alias Born 01/24/2004

Re: cjgaddy post# 278797

Friday, 11/18/2016 11:01:17 AM

Friday, November 18, 2016 11:01:17 AM

Post# of 347009
12-8-16: Freimark/Hutchins Poster at Annual SanAntonio-Breast-Cancer-Symposium, “PS-Targeting Enhances Anti-LAG3 in Murine Breast Cancer Tumors”

Dec6-10 2016: “39th Annual San Antonio Breast Cancer Symposium”
“...presented by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, AACR, and Baylor College of Medicine. The driving force behind this collaboration is the shared mission of the organizations to advance progress against breast cancer. As exciting strides are made in the field of breast cancer research & treatment, our program continues to present essential up-to-the minute info. combined with engrossing discussion for basic, translational, and clinical cancer research professionals.
SABCS'16 is designed to provide state-of-the-art info. on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer & premalignant breast disease, to an intl. audience of academic, private physicians, and researchers. We anticipate 7,500 attendees from more than 90 countries.”
http://www.sabcs.org
https://www.sabcs.org/Program/Poster-Sessions/Poster-Session-2
TRACK: Tumor Cell & Molecular Biology: Immunology & Preclin. Immunotherapy
12-8-16 7:30–9:00am Poster Session 2
#P2-04-12: “Targeting of Phosphatidylserine by Monoclonal Antibodies Enhances the Activity of Immune Checkpoint Lag3 Targeting Antibodies in Murine Breast Tumors” - Gray MJ, Gong J, Jeff Hutchins, Bruce D. Freimark (Dir.Res/Preclin.Oncology) - Peregrine Pharmaceuticals

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y